Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Share-based Compensation (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Share-based Compensation for 2 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 424.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $329229.0, a N/A change, with the full-year FY2025 number at $163772.0, down 79.9% from a year prior.
  • Share-based Compensation was $100000.0 for Q4 2025 at Neuphoria Therapeutics, down from $111277.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $111277.0 in Q3 2025 to a low of $19084.0 in Q4 2024.